Oruka Therapeutics, Inc. 10-K Summary: A Year of Transformation and Pipeline Acceleration

Oruka Therapeutics, Inc. (NASDAQ: ORKA) experienced a pivotal year, marked by significant corporate transformation and rapid advancement of its innovative drug pipeline. This summary provides a comprehensive overview of the company's performance and future outlook, based on its Annual Report (10-K) for the fiscal year ended December 31, 2025.

Business Overview: Company Overview & Mission

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic inflammatory and immune-mediated diseases, especially severe skin conditions like psoriasis (PsO). The company emerged from the merger of ARCA biopharma, Inc. and Pre-Merger Oruka, which finalized on August 29, 2024. Following the merger, ARCA biopharma adopted the new name and ticker symbol 'ORKA' (formerly 'ABIO').

Oruka's core strategy involves using advanced antibody engineering to create cutting-edge monoclonal antibody therapies. The company aims to significantly improve existing treatments by enhancing efficacy, safety, and, crucially, patient convenience through less frequent dosing. Its name, "Oruka," meaning "restoration" for skin, highlights its commitment to offering greater freedom and relief to patients suffering from chronic skin diseases.

Financial Performance (Fiscal Year Ended December 31, 2025)

As a clinical-stage company, Oruka Therapeutics generated minimal product revenue during the fiscal year.

• Revenue: $0.5 million, primarily from grants or collaboration agreements.
• Net Loss: $(82.3) million, driven by substantial investment in research and development.
• Market Capitalization: As of June 30, 2025, Oruka Therapeutics had a market capitalization of approximately $371.5 million.
• Smaller Reporting Company Status: Oruka qualifies as a "smaller reporting company." While this status streamlines administrative processes, it also means investors may receive less detailed financial and operational information compared to larger pharmaceutical companies.

Management Discussion and Analysis (MD&A) Highlights

Management highlighted significant investment in research and development as the primary driver of the net loss, consistent with Oruka's clinical-stage status and aggressive pipeline advancement. The company generated $0.5 million in revenue, primarily from grants or collaboration agreements rather than product sales. Oruka's operations consumed $75.0 million in cash during the year. These funds covered advancing ORKA-001 into Phase 2 studies, ORKA-002 into Phase 1/2 development, and general administrative expenses as a public company post-merger.

Management projects that current cash and short-term investments will fund operations into late 2027. However, this projection may change based on the pace and success of clinical trials, strategic decisions, and potential business development activities. The company anticipates future capital raises to support continued pipeline development and potential commercialization efforts.

Financial Health

As of December 31, 2025, Oruka Therapeutics held a strong cash position of $120.5 million in cash and short-term investments. The company reported no significant long-term debt. This cash balance, alongside a projected operating cash burn of $75.0 million for 2025, should provide sufficient liquidity to fund operations into late 2027. However, as a clinical-stage entity with no product revenue, Oruka's long-term financial health depends on successful clinical development, regulatory approvals, and future capital raises to support its expanding research and development.

Pipeline Progress: Advancing Novel Treatments

Oruka is rapidly advancing a pipeline of innovative monoclonal antibody candidates, engineered for significantly extended dosing intervals.

1. ORKA-001 (Psoriasis)

   • Mechanism: Targets IL-23p19, a key protein driving psoriasis inflammation.
   • Differentiation: Engineered for an ultra-long half-life, it aims for once or twice-yearly subcutaneous dosing, a significant improvement over current monthly or quarterly regimens.
   • Key Milestones (2025):
     • Oruka initiated its first-in-human (Phase 1) trial in late 2024.
     • In September 2025, the company announced positive early Phase 1 results, demonstrating an approximate 100-day half-life, effective and sustained IL-23 pathway blockade for at least 24 weeks, and a favorable safety and tolerability profile.
     • In late 2025, Oruka initiated two larger Phase 2 studies: a Phase 2a study to evaluate dose-ranging and efficacy, and a Phase 2b study specifically designed to assess the potential for yearly dosing in patients with moderate-to-severe psoriasis.
   • Upcoming Data Readouts: Oruka anticipates topline data from the Phase 2a study in the second quarter of 2026, with further long-term data later in 2026. The company projects data from the Phase 2b study for 2027.

2. ORKA-002 (Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis)

   • Mechanism: Targets both IL-17A and IL-17F, which are key inflammatory proteins. Blocking both has shown superior effectiveness in some inflammatory conditions compared to targeting only IL-17A.
   • Differentiation: Also engineered for an extended half-life, it offers potential for twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa (HS).
   • Key Milestones (Early 2026):
     • In January 2026, Oruka reported positive early Phase 1 results, showing an approximate 75-80 day half-life, sustained IL-17 pathway blockade for 24 weeks, and a good safety profile.
     • In February 2026, Oruka commenced a Phase 2 study for moderate-to-severe psoriasis.
   • Upcoming Data Readouts: The company expects topline data from the psoriasis Phase 2 study in 2027. Oruka plans to initiate a separate Phase 2 study for hidradenitis suppurativa in the second half of 2026.

3. ORKA-003 (Undisclosed Program)

   • Oruka maintains a third preclinical program, ORKA-003, targeting a novel, undisclosed pathway, signaling future pipeline expansion.

Future Outlook: Strategic Vision

Oruka considers ORKA-001 and ORKA-002 complementary assets, providing different therapeutic approaches based on a patient's disease profile (e.g., IL-23 for skin-focused psoriasis, IL-17 for broader inflammatory involvement including joints). The company is also exploring a combination therapy, ORKA-021, which would combine the rapid action of an IL-17 blocker with the sustained efficacy of an IL-23 blocker.

Oruka's overarching strategy is to continue innovating through advanced antibody engineering, developing best-in-class or first-in-class therapies that significantly improve patient outcomes and adherence through less frequent dosing. For commercialization, Oruka is evaluating various strategies, such as potential partnerships with larger pharmaceutical companies for late-stage development and global market access, or building its own commercial infrastructure for specific markets if clinical data supports it.

Competitive Position

Oruka Therapeutics targets highly competitive therapeutic areas, particularly psoriasis and other inflammatory and immune-mediated diseases. The market includes numerous established pharmaceutical companies with approved therapies, as well as a robust pipeline of investigational drugs. Existing treatments for psoriasis, for instance, include various biologics targeting IL-17, IL-23, and TNF pathways, alongside oral small molecules and topical agents.

Oruka aims to differentiate ORKA-001 and ORKA-002 primarily through their engineered ultra-long half-lives, which allow for significantly extended dosing intervals (e.g., once or twice-yearly for ORKA-001) compared to current standards. This potential for enhanced patient convenience and adherence forms Oruka's key competitive strategy. The company also believes its dual-targeting approach with ORKA-002 (IL-17A/F) offers a differentiated mechanism that could provide superior efficacy in certain patient populations. However, successful competition will depend on demonstrating superior efficacy, safety, and convenience in clinical trials, securing regulatory approval, and achieving market acceptance against well-entrenched competitors.

Risk Factors: Key Risks for Investors

Investing in Oruka Therapeutics carries significant risks inherent to clinical-stage biotechnology companies:

• Clinical Trial Success & Regulatory Approval: Oruka's business success hinges almost entirely on the successful outcome of its clinical trials (Phase 1, 2, and 3) and subsequent regulatory approvals from agencies like the FDA. There is no guarantee that any product candidate will prove safe and effective, or receive approval. Clinical trials are lengthy, expensive, and often fail.
• Funding & Dilution: As a company with no current product revenue and a significant cash burn rate, Oruka will need substantial additional capital to complete clinical development, pursue regulatory approvals, and potentially commercialize its product candidates. This future funding may come from equity offerings, potentially diluting existing shareholders, or debt financing, which could impose restrictive covenants.
• Competition: The markets for psoriasis and other inflammatory diseases are highly competitive, with numerous approved therapies and many more in development by large, well-established pharmaceutical companies. Oruka's product candidates must demonstrate superior efficacy, safety, or convenience to gain market share.
• Intellectual Property: Oruka's success depends on its ability to obtain and maintain patent protection for its product candidates and proprietary technology. Challenges to its patents or the inability to secure new patents could significantly harm its competitive position.
• Market Acceptance: Even if approved, Oruka's products may not gain wide acceptance from patients, physicians, or payers, especially given existing treatments.
• Dependence on Key Personnel: The company's success relies heavily on attracting and retaining highly qualified scientific, clinical, and management personnel.
• Manufacturing Risks: Oruka relies on third-party manufacturers for its drug supplies. Any disruptions in manufacturing or quality control issues could delay clinical trials or commercialization.

Investor Takeaway

Oruka Therapeutics, Inc. experienced a transformative year, marked by a significant merger and rapid advancement of its lead pipeline assets into mid-stage clinical trials. Its focus on developing long-acting, differentiated monoclonal antibodies for chronic inflammatory conditions presents a compelling value proposition if successful, especially the potential for significantly reduced dosing frequency. However, as a clinical-stage biotech, Oruka remains a high-risk, high-reward investment. Investors should carefully weigh the promising clinical progress and strategic vision against the substantial financial requirements, competitive landscape, and inherent uncertainties of drug development and regulatory approval. Upcoming data readouts in 2026 and 2027 will serve as critical catalysts for the company's future trajectory.